

107568817

USSN Not yet assigned

WOLLIN

Page 1 of 1

1AP20 Rec'd PTO 21 FEB 2006

Appendix C

Abstract of the Disclosure

The invention relates to the combined administration of a pulmonary surfactant and a PDE2 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 2 (PDE2) activity is detrimental.